 |
|
| News Archive |
| Click on a news topic below to view the details |
|
1)
March 2008 - Our CLIA certified laboratory LabPMM™ was created to facilitate access to Personalized Molecular Diagnostics™.
2) January, 2008 - Determination of IGHV gene mutational status in chronic lymphocytic leukemia: bioinformatics advances meet clinical needs “Over the past few years, the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes has proved to be a major determinant in the prognostic evaluation of chronic lympho..."
3) October 2007 - The IVS 2007 AMP Travel Award is announced. InVivoScribe Technologies is pleased to announce that the recipient of our 2007 AMP Travel Award is Hongxiang Liu, PhD from the Department of Histopathology at Addenbrooke’s Hospital
4) October 2007 - FIRE UPDATE: IVS remains fully operational. However, our shipping providers have experienced disruptions due to the fires here in San Diego. We expect to be back to a normal shipping schedule Monday, Oct. 29th. 5) June 2007 - The IVS 2007 EHA Travel Award is announced. The IVS 2007 EHA Travel Award is announced.
6) April 2007 - InVivoScribe Technologies to offer clinical diagnostic testing services. InVivoScribe Technologies to offer clinical diagnostic testing services.
7) July 2006 - IVS obtains exclusive license to FLT3 mutation detection patents. IVS obtains exclusive license to FLT3 mutation detection patents.
8) May 2006 - Peer-Reviewed Study Confirms Product Performance The Mayo Clinic recently published an independent validation of our gene clonality primer sets.
9) April 2006 - InVivoScribe releases IdentiClone™ Assays. CE-marked in vitro diagnostic products for our European customers. These diagnostic products are available for Applied Biosystems & Beckman-Coulter instruments as well as standard gel detection formats.
10) April 2006 - InVivoScribe releases IGH Somatic Hypermutation tests for chronic lymphocytic leukemia (CLL) Hypermutation status provides important prognostic information for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Hypermutation of the IGH gene is strongly pred
11) February 2006 - InVivoScribe to release Somatic Hypermutation tests for chronic lymphocytic leukemia (CLL) on April 1, 2006 12) February 2006 - New and improved IGH Framework 2 (v2) master mix is available for all detection formats New and improved IGH Framework 2 (v2) master mix is available for all detection formats. This improved reagent can be used...
13) January 2006 - InVivoScribe to release CE marked diagnostic products for the European market on April 1, 2006. These products will be formatted for Applied Biosystems & Beckman-Coulter instruments as well as...
14) November 2005 - NEW! LymphoTrack ™ assays for Minimal Residual Disease detection of IGH gene rearrangements Assays for Minimal Residual Disease detection of IGH gene rearrangements ...
15) August 2005 - InVivoScribe Technologies, SARL opens in Provence, France Dr. Jeffrey Miller, founder and President of IVS, has returned from France, where he opened a subsidiary on the Mediterranean coastal city of La Ciotat, near Marseille. "Opening InVivoScribe Technologies, SARL, establishes a direct presence...
16) May 2005 - NEW! JAK2 (Janus Kinase 2) V617F Activating Mutation Assay Released Robust single day assay is used to rapidly identify the clonal JAK2 V617F mutation...
17) November 2004 - Beckman Coulter Vidiera™ NsD & CEQ™ Series Detection System Assays Beckman Coulter and InVivoScribe Technologies have signed a long-term collaborative development agreement...
18) July 2004 - BIOMED-2 Agreement InVivoScribe Technologies finalized a long-term, world wide exclusive licensing agreement with the BIOMED-2 Concerted Action Group...
19) April 16, 2004 - Production Space - Certified ISO class 5 Our production space is certified ISO class 5 per International Standard ISO 14644...
20) April 16, 2004 - IVS to develop commercial reagents IVS initiates program to develop commercial reagents to practice our proprietary in vivo cDNA synthesis and template primer cDNA synthesis technologies.
21) April 14, 2004 - New Molecular Pathology Products catalog now available Our new Molecular Pathology Products catalog is now available.
22) April 2004 - IVS expands patent licensing program IVS is currently offering sublicenses to our exclusive licensed patents that cover PCR-based detection...
23) March 15, 2004 - IVS beats Revenue Target IVS decisively beats revenue target projections for 1Q 2004.
24) January 26, 2004 - IVS retires all remaining corporate debt All remaining corporate dept is now retired!
25) January 15, 2004 - New Production Space Complete IVS completes buildout of new production space, designed to specifications per International Standard ISO 14644.
26) January 1, 2004 - Move in complete- New Production Space IVS completes move into new facility and hires additional staff to assist with research & development, production, documentation, quality control, and technical service.
27) December 1, 2003 - MRD testing program Initiated IVS initiates minimal residual disease (MRD) testing program designed to identify and track a wide variety of leukemias and lymphomas...
28) November 15, 2003 - 12-fold expansion into larger facility initiated. Today, Invivoscribe initiated expansion into much larger facility (12-fold expansion). Move expected to be completed by January 1, 2004...
29) September 16, 2003 - IVS meets its projected revenue target for 2003 Additional laboratory space identified for expansion. Expansion scheduled for 4Q 2003.
30) September 2003 - I.T. Team Completes new Website! Our I.T. team has designed a completely new website including a graphics-rich, easier to navigate online catalog and ordering system.
31) September 2003 - Many patent sublicensing agreements finalized IVS has finalized a number of additional patent sublicensing agreements. To date sublicensees include corporations, reference laboratories,...
32) August 2003 - FLT3 Mutation Assays release announced IVS announces release of the FLT3 Mutation Assays. These assays (available in both gel detection and ABI fluorescence detection formats) identify both internal tandem duplications and...
33) May 6, 2003 - ARUP Laboratories sublicenses technology from InVivoScribe ARUP Laboratories sublicenses technology from InVivoScribe, press release available for download here.
34) January 2003 - IVS announces sales growth of over 570% During the last two years IVS has grown over 570%. Growth in 2003 expected to exceed growth experienced in any previous year.
35) December 24, 2002 - Patents now cover in vivo cDNA synthesis technologies issues U.S. Patent numbered 6,498,025 covering in vivo cDNA synthesis technologies issues. This dominant patent covers complementary DNA synthesis. The patent expires in December of 2019.
36) November 2002 - U.S. Patent numbered 6,498,025 covering in vivo cDNA synthesis technologies issued...covers complementary DNA synthesis InVivoScribe Technologies (IVS) acquires a world-wide exclusive license to patents that cover PCR-based testing and monitoring of the immunoglobulin and T cell receptor loci... IVS is negotiating to sell a number of commercial sublicenses to these patents.
37) November 2002 - IVS expands operations in Europe IVS expands operations in Europe, releasing BIOMED2 assays in collaboration with 32 laboratories in Europe...
|